India Cuts Drug Trial Manufacturing Review Timeline in Half to Accelerate Pharmaceutical Development
核心洞察
The Indian government has reduced the review period for manufacturing applications for new drugs from 90 to 45 working days to accelerate pharmaceutical development.
Manufacturers can now initiate clinical trials or bioequivalence studies with prior notification to regulators instead of requiring express permission.
The new rules allow companies to start manufacturing investigational drugs for analytical and non-clinical testing based on acknowledgment of intimation alone.
The Indian government has implemented significant regulatory reforms to accelerate pharmaceutical development by cutting the review timeline for drug trial manufacturing applications in half. The Health Ministry (搜索) announced that manufacturers seeking to produce new drugs or investigational drugs for clinical trials will now receive approval within 45 working days, down from the previous 90-day requirement.
Streamlined Approval Process
Under the amended New Drugs and Clinical Trials Rules, manufacturers can now initiate clinical trials or bioequivalence studies through a simplified "prior intimation" system rather than obtaining express permission from regulators. This represents a fundamental shift in the regulatory approach, moving from a permission-based to a notification-based system for certain categories of drug manufacturing.
For analytical and non-clinical testing of drugs—excluding sex hormones (搜索), cytotoxic drugs (搜索), beta lactam (搜索) antibiotics, biologics (搜索) with live microorganisms, and narcotics (搜索) and psychotropic substances—companies can submit online applications and begin manufacturing based solely on acknowledgment of their notification.
Regulatory Framework Changes
The amendments to the New Drugs and Clinical Trials Rules, 2019, were finalized following stakeholder consultations and recommendations from the Drugs Technical Advisory Board (搜索) (DTAB). At its 92nd meeting, the DTAB specifically recommended reducing permission process timelines from 90 to 45 working days while introducing the notification system for preclinical and analytical testing applications.
The notification states that "in the sub-rule (1), for the words 'ninety working days' wherever they occur, the words 'forty-five working days' shall be substituted." Additionally, the marginal heading has been amended to substitute "permission" with "permission or prior intimation."
Industry Impact and Implementation
According to industry experts, these changes will significantly accelerate the manufacturing of new and investigational drugs while facilitating exports by making the process less time-consuming. Previously, manufacturers were required to obtain permission through Form CT-10 from the Central Licensing Authority (搜索) before manufacturing new drugs or investigational drugs for clinical trials.
An industry insider noted that "earlier manufacturers were supposed to take permission by applying in Form CT-10 to the Central Licensing Authority (搜索) to manufacture such new drugs or investigational new drugs...It was time consuming. The change will be of significant help."
The new rules, officially titled the "New Drugs and Clinical Trials (Amendment) Rules, 2026," will come into force 45 days from the date of notification, effective March 6, 2025. The Health Ministry (搜索) had previously invited public suggestions and objections on these proposed changes, which were reviewed before finalizing the amendments.
Compliance Requirements
Under the new framework, applicants must ensure that new drugs manufactured under this system are used exclusively for conducting clinical trials, bioavailability and bioequivalence studies, or for examination, testing, and analysis. The rules explicitly state that no part of these drugs shall be sold in the market or supplied to any other person, agency, institution, or organization.